Cdc7 Inhibitor Tablet Composition Dry Granulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pharmaceutical compositions for Cdc7 kinase inhibitors face challenges in stability and manufacturability, particularly in achieving optimal weight ratios of drug substance to compressible fillers, which affect the stability and flowability of tablets.
Innovation Solution
A tablet composition comprising Compound 1, silicified microcrystalline cellulose (SMCC), mannitol, polyvinylpyrrolidone (PVP), croscarmellose sodium, and anhydrous lactose, produced through a dry granulation process, with specific weight ratios and excipient distributions to enhance stability and flowability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If the weight ratio of drug substance to compressible filler is increased to improve stability, then the stability improves, but the flowability deteriorates
Solution Approach 1:
The patent optimizes the weight ratio parameters of drug substance to compressible filler within specific ranges (1:0.8 to 1:1.2) to achieve optimal balance between stability and flowability. This parameter optimization resolves the contradiction by identifying the precise ratio range where both requirements are satisfied simultaneously.
Solution Approach 2:
The patent uses a composite filler system combining multiple materials (silicified microcrystalline cellulose, anhydrous lactose, and mannitol) in specific proportions. This composite approach leverages the complementary properties of each filler to maintain both stability and flowability, overcoming the limitations of single-fillers at high drug substance ratios.
2Ease of operation
If the weight ratio of drug substance to compressible filler is decreased to improve flowability, then the flowability improves, but the stability deteriorates
Solution Approach 1:
The patent establishes specific weight ratio ranges (1:0.8 to 1:1.2) that optimize both flowability and stability simultaneously, avoiding the extremes that would compromise either property. This parameter control resolves the contradiction by defining the optimal operating window.
Solution Approach 2:
The multi-component filler composite (SMCC, anhydrous lactose, mannitol) provides enhanced flowability even at lower filler ratios while maintaining stability through the synergistic properties of the combined materials, resolving the trade-off between flowability and stability.
3Ease of manufacture
If conventional pharmaceutical composition methods are used, then the manufacturing process is simple, but the manufacturability and stability are insufficient
Solution Approach 1:
The patent specifies precise weight ratio parameters and composition proportions that optimize both manufacturing performance and product stability. These controlled parameters enable reliable manufacturing outcomes while maintaining process simplicity, resolving the contradiction between ease of manufacture and manufacturability reliability.
Data Source
Figure 1~2(c)
AI summary
The present disclosure relates to pharmaceutical compositions comprising Compound 1 and/or tautomers thereof, or a pharmaceutically acceptable salt or hydrate thereof. The pharmaceutical compositions may comprise microcrystalline cellulose, e.g., silicified microcrystalline cellulose, as a compressible filler. The pharmaceutical compositions may be produced by a method comprising dry granulation process. The pharmaceutical compositions may comprise a weight ratio of the Compound 1 drug substance to intra-granular compressible filler of greater than 1:1.